Drug firm Lupin has received approval from the US health regulator to market its generic Doxycycline hyclate tablets, used for treatment of infections, in the American market.
The company has received final approval from the United States Food and Drug Administration (US FDA) to market its Doxycycline hyclate tablets USP in the strength of 100 mg, Lupin said in a BSE filing.
The company’s product is a generic version of Pfizer Inc’s Vibra tablets in the same strength, it added.
According to IMS MAT June 2017 data, Doxycycline hyclate tablets USP in 100 mg strength had US sales of $149.9 million, Lupin said.
The tablets are indicated for the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne, it added.
Shares of Lupin were trading 1.02 per cent higher at Rs 978 per scrip on BSE.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.